← Drug database

Truvada (emtricitabine;tenofovir disoproxil)

Region
🇪🇺 EU
Active substance
emtricitabine;tenofovir disoproxil
Company
Gilead Sciences Ireland UC
Status
Authorised
Therapeutic area
HIV Infections
CHMP opinion
Thu 18 Nov 2004
EU approval
Sun 20 Feb 2005
Application
EMEA/H/C/000594
ATC
J05AR03
Official record
www.ema.europa.eu

Indication

Treatment of HIV-1 infection: Truvada is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults. Truvada is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years. Pre-exposure prophylaxis (PrEP): Truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Truvada

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.